Circulation. 2003;108:661-663
Published online before print August 4, 2003, doi: 10.1161/01.CIR.0000086981.09834.E0
Published online before print August 4, 2003, doi: 10.1161/01.CIR.0000086981.09834.E0
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;108:661.)
© 2003 American Heart Association, Inc.
Brief Rapid Communications |
Overexpression of Apolipoprotein A-I Promotes Reverse Transport of Cholesterol From Macrophages to Feces In Vivo
From the Departments of Medicine (Y.Z., M.R., D.J.R.) and Cell and Developmental Biology (J.M.G.) and the Center for Experimental Therapeutics (Y.Z., M.R., D.J.R.), University of Pennsylvania School of Medicine, Philadelphia, Pa; and the Children’s Hospital of Philadelphia (I.Z., G.H.R.), Philadelphia, Pa.
Correspondence to Daniel J. Rader, MD, University of Pennsylvania Medical Center, 654 Biomedical Research Building II/III, 421 Curie Blvd, Philadelphia, PA 19104. E-mail rader{at}mail.med.upenn.edu
Received March 11, 2003; revision received June 18, 2003; accepted June 19, 2003.
Background— Abundant data indicate that overexpression of apolipoprotein A-I (apoA-I) in mice inhibits atherosclerosis. One mechanism is believed to be promotion of reverse cholesterol transport, but no direct proof of this concept exists. We developed a novel approach to trace reverse transport of labeled cholesterol specifically from macrophages to the liver and feces in vivo and have applied this approach to investigate the ability of apoA-I overexpression to promote macrophage-specific reverse cholesterol transport.
Method and Results— J774 macrophages were loaded with cholesterol by incubation with acetylated LDL, labeled with 3H-cholesterol, and then injected intraperitoneally into mice. Plasma and feces were collected at 24 hours and 48 hours, when mice were exsanguinated, tissues were harvested, and all were analyzed for tracer counts. 3H-cholesterol was found in the plasma, liver, and feces. For apoA-I overexpression, mice were injected intravenously with apoA-I adenovirus (1011 particles per animal) 3 days before labeled macrophages were injected. ApoA-I overexpression led to significantly higher 3H-cholesterol in plasma, liver, and feces. The amount of 3H-tracer in the liver was 35% higher (P<0.05) and the 3H-tracer excreted into feces over 48 hours was 63% higher (P<0.05) in apoA-I–expressing mice than in control mice.
Conclusion— Injection of 3H-cholesterol–labeled macrophage foam cells is a method of measuring reverse cholesterol transport specifically from macrophages to feces in vivo, and apoA-I overexpression promotes macrophage-specific reverse cholesterol transport.
Key Words: cholesterol • cholesterol, reverse transport • apolipoproteins • macrophages • atherosclerosis
This article has been cited by other articles:
 |
|
 |
|
  T. Nishimoto, M. A. Pellizzon, M. Aihara, I. M. Stylianou, J. T. Billheimer, G. Rothblat, and D. J. Rader Fish Oil Promotes Macrophage Reverse Cholesterol Transport in Mice Arterioscler Thromb Vasc Biol, October 1, 2009; 29(10): 1502 - 1508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Liu, C. Huan, M. Chakraborty, H. Zhang, D. Lu, M.-S. Kuo, G. Cao, and X.-C. Jiang Macrophage Sphingomyelin Synthase 2 Deficiency Decreases Atherosclerosis in Mice Circ. Res., July 31, 2009; 105(3): 295 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tanigawa, J. T. Billheimer, J.-i. Tohyama, I. V. Fuki, D. S. Ng, G. H. Rothblat, and D. J. Rader Lecithin: Cholesterol Acyltransferase Expression Has Minimal Effects on Macrophage Reverse Cholesterol Transport In Vivo Circulation, July 14, 2009; 120(2): 160 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. R. Moreno, J. Sanz, and V. Fuster Promoting Mechanisms of Vascular Health: Circulating Progenitor Cells, Angiogenesis, and Reverse Cholesterol Transport J. Am. Coll. Cardiol., June 23, 2009; 53(25): 2315 - 2323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Otera, T. Ishida, T. Nishiuma, K. Kobayashi, Y. Kotani, T. Yasuda, R. K. Kundu, T. Quertermous, K.-i. Hirata, and Y. Nishimura Targeted inactivation of endothelial lipase attenuates lung allergic inflammation through raising plasma HDL level and inhibiting eosinophil infiltration Am J Physiol Lung Cell Mol Physiol, April 1, 2009; 296(4): L594 - L602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Rader, E. T. Alexander, G. L. Weibel, J. Billheimer, and G. H. Rothblat The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis J. Lipid Res., April 1, 2009; 50(Supplement): S189 - S194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. C. McGillicuddy, M. de la Llera Moya, C. C. Hinkle, M. R. Joshi, E. H. Chiquoine, J. T. Billheimer, G. H. Rothblat, and M. P. Reilly Inflammation Impairs Reverse Cholesterol Transport In Vivo Circulation, March 3, 2009; 119(8): 1135 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Zhao, J. Song, and S. Ghosh Hepatic overexpression of cholesteryl ester hydrolase enhances cholesterol elimination and in vivo reverse cholesterol transport J. Lipid Res., October 1, 2008; 49(10): 2212 - 2217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Calpe-Berdiel, N. Rotllan, C. Fievet, R. Roig, F. Blanco-Vaca, and J. C. Escola-Gil Liver X receptor-mediated activation of reverse cholesterol transport from macrophages to feces in vivo requires ABCG5/G8 J. Lipid Res., September 1, 2008; 49(9): 1904 - 1911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Sehayek and S. L. Hazen Cholesterol Absorption From the Intestine Is a Major Determinant of Reverse Cholesterol Transport From Peripheral Tissue Macrophages Arterioscler Thromb Vasc Biol, July 1, 2008; 28(7): 1296 - 1297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. deGoma, R. L. deGoma, and D. J. Rader Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J. Am. Coll. Cardiol., June 10, 2008; 51(23): 2199 - 2211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Zanotti, F. Poti, M. Pedrelli, E. Favari, E. Moleri, G. Franceschini, L. Calabresi, and F. Bernini The LXR agonist T0901317 promotes the reverse cholesterol transport from macrophages by increasing plasma efflux potential J. Lipid Res., May 1, 2008; 49(5): 954 - 960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Araujo, B. Barajas, M. Kleinman, X. Wang, B. J. Bennett, K. W. Gong, M. Navab, J. Harkema, C. Sioutas, A. J. Lusis, et al. Ambient Particulate Pollutants in the Ultrafine Range Promote Early Atherosclerosis and Systemic Oxidative Stress Circ. Res., March 14, 2008; 102(5): 589 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Troutt, W. E. Alborn, M. K. Mosior, J. Dai, A. T. Murphy, T. P. Beyer, Y. Zhang, G. Cao, and R. J. Konrad An apolipoprotein A-I mimetic dose-dependently increases the formation of pre{beta}1 HDL in human plasma J. Lipid Res., March 1, 2008; 49(3): 581 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Tchoua, W. D'Souza, N. Mukhamedova, D. Blum, E. Niesor, J. Mizrahi, C. Maugeais, and D. Sviridov The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport Cardiovasc Res, March 1, 2008; 77(4): 732 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Levy High-density lipoprotein mass, cholesteryl ester transport protein, and macrophage reverse cholesterol transport: from the bedside back to the bench Cardiovasc Res, March 1, 2008; 77(4): 614 - 615. [Full Text] [PDF]
|
|
|
|
|
|
M. P. Adorni, F. Zimetti, J. T. Billheimer, N. Wang, D. J. Rader, M. C. Phillips, and G. H. Rothblat The roles of different pathways in the release of cholesterol from macrophages J. Lipid Res., November 1, 2007; 48(11): 2453 - 2462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kockx, D. L. Guo, T. Huby, P. Lesnik, J. Kay, T. Sabaretnam, E. Jary, M. Hill, K. Gaus, J. Chapman, et al. Secretion of Apolipoprotein E From Macrophages Occurs via a Protein Kinase A and Calcium-Dependent Pathway Along the Microtubule Network Circ. Res., September 14, 2007; 101(6): 607 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tanigawa, J. T. Billheimer, J.-i. Tohyama, Y. Zhang, G. Rothblat, and D. J. Rader Expression of Cholesteryl Ester Transfer Protein in Mice Promotes Macrophage Reverse Cholesterol Transport Circulation, September 11, 2007; 116(11): 1267 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-D. Wang, V. Franklin, and Y. L. Marcel In Vivo Reverse Cholesterol Transport From Macrophages Lacking ABCA1 Expression Is Impaired Arterioscler Thromb Vasc Biol, August 1, 2007; 27(8): 1837 - 1842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Asleh, R. Miller-Lotan, M. Aviram, T. Hayek, M. Yulish, J. E. Levy, B. Miller, S. Blum, U. Milman, C. Shapira, et al. Haptoglobin Genotype Is a Regulator of Reverse Cholesterol Transport in Diabetes In Vitro and In Vivo Circ. Res., December 8, 2006; 99(12): 1419 - 1425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M McMahon, J Grossman, W Chen, and B H Hahn Inflammation and the pathogenesis of atherosclerosis in systemic lupus erythematosus Lupus, November 1, 2006; 15(11_suppl): 59 - 69. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Rashid, B. W. Patterson, and G. F. Lewis Thematic review series: Patient-Oriented Research. What have we learned about HDL metabolism from kinetics studies in humans? J. Lipid Res., August 1, 2006; 47(8): 1631 - 1642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Y. Han, T. Chiba, J. S. Campbell, N. Fausto, M. Chaisson, G. Orasanu, J. Plutzky, and A. Chait Reciprocal and Coordinate Regulation of Serum Amyloid A Versus Apolipoprotein A-I and Paraoxonase-1 by Inflammation in Murine Hepatocytes Arterioscler Thromb Vasc Biol, August 1, 2006; 26(8): 1806 - 1813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Zschenker, T. Illies, and D. Ameis Overexpression of lysosomal Acid lipase and other proteins in atherosclerosis. J. Biochem., July 1, 2006; 140(1): 23 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cuchel and D. J. Rader Macrophage Reverse Cholesterol Transport: Key to the Regression of Atherosclerosis? Circulation, May 30, 2006; 113(21): 2548 - 2555. [Full Text] [PDF]
|
|
|
|
|
|
C. Tso, G. Martinic, W.-H. Fan, C. Rogers, K.-A. Rye, and P. J. Barter High-Density Lipoproteins Enhance Progenitor-Mediated Endothelium Repair in Mice Arterioscler Thromb Vasc Biol, May 1, 2006; 26(5): 1144 - 1149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H.E.M. Klerkx, K. E. Harchaoui, W. A. van der Steeg, S. M. Boekholdt, E. S.G. Stroes, J. J.P. Kastelein, and J. A. Kuivenhoven Cholesteryl Ester Transfer Protein (CETP) Inhibition Beyond Raising High-Density Lipoprotein Cholesterol Levels: Pathways by Which Modulation of CETP Activity May Alter Atherogenesis Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 706 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Duffy and D. J. Rader Emerging Therapies Targeting High-Density Lipoprotein Metabolism and Reverse Cholesterol Transport Circulation, February 28, 2006; 113(8): 1140 - 1150. [Full Text] [PDF]
|
|
|
|
|
|
S. U. Naik, X. Wang, J. S. Da Silva, M. Jaye, C. H. Macphee, M. P. Reilly, J. T. Billheimer, G. H. Rothblat, and D. J. Rader Pharmacological Activation of Liver X Receptors Promotes Reverse Cholesterol Transport In Vivo Circulation, January 3, 2006; 113(1): 90 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Moore, M. Navab, J. S. Millar, F. Zimetti, S. Hama, G. H. Rothblat, and D. J. Rader Increased Atherosclerosis in Mice Lacking Apolipoprotein A-I Attributable to Both Impaired Reverse Cholesterol Transport and Increased Inflammation Circ. Res., October 14, 2005; 97(8): 763 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.-Q. Peng, Z. Wu, G. Brubaker, L. Zheng, M. Settle, E. Gross, M. Kinter, S. L. Hazen, and J. D. Smith Tyrosine Modification Is Not Required for Myeloperoxidase-induced Loss of Apolipoprotein A-I Functional Activities J. Biol. Chem., October 7, 2005; 280(40): 33775 - 33784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, P. R. Moreno, Z. A. Fayad, R. Corti, and J. J. Badimon Atherothrombosis and High-Risk Plaque: Part I: Evolving Concepts J. Am. Coll. Cardiol., September 20, 2005; 46(6): 937 - 954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Navab, G.M. Anantharamaiah, S. T. Reddy, S. Hama, G. Hough, J. S. Frank, V. R. Grijalva, V. K. Ganesh, V. K. Mishra, M. N. Palgunachari, et al. Oral Small Peptides Render HDL Antiinflammatory in Mice and Monkeys and Reduce Atherosclerosis in ApoE Null Mice Circ. Res., September 16, 2005; 97(6): 524 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Rotllan, V. Ribas, L. Calpe-Berdiel, J. M. Martin-Campos, F. Blanco-Vaca, and J. C. Escola-Gil Overexpression of Human Apolipoprotein A-II in Transgenic Mice Does Not Impair Macrophage-Specific Reverse Cholesterol Transport In Vivo Arterioscler Thromb Vasc Biol, September 1, 2005; 25(9): e128 - e132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Navab, G.M. Anantharamaiah, S. T. Reddy, S. Hama, G. Hough, V. R. Grijalva, N. Yu, B. J. Ansell, G. Datta, D. W. Garber, et al. Apolipoprotein A-I Mimetic Peptides Arterioscler Thromb Vasc Biol, July 1, 2005; 25(7): 1325 - 1331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. F. Lewis and D. J. Rader New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport Circ. Res., June 24, 2005; 96(12): 1221 - 1232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Escher, A. Hoang, S. Georges, U. Tchoua, A. El-Osta, Z. Krozowski, and D. Sviridov Demethylation using the epigenetic modifier, 5-azacytidine, increases the efficiency of transient transfection of macrophages J. Lipid Res., February 1, 2005; 46(2): 356 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Barter, S. Nicholls, K.-A. Rye, G.M. Anantharamaiah, M. Navab, and A. M. Fogelman Antiinflammatory Properties of HDL Circ. Res., October 15, 2004; 95(8): 764 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Navab, G.M. Anantharamaiah, S. T. Reddy, S. Hama, G. Hough, V. R. Grijalva, A. C. Wagner, J. S. Frank, G. Datta, D. Garber, et al. Oral D-4F Causes Formation of Pre-{beta} High-Density Lipoprotein and Improves High-Density Lipoprotein-Mediated Cholesterol Efflux and Reverse Cholesterol Transport From Macrophages in Apolipoprotein E-Null Mice Circulation, June 29, 2004; 109(25): 3215 - 3220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Navab, G. M. Ananthramaiah, S. T. Reddy, B. J. Van Lenten, B. J. Ansell, G. C. Fonarow, K. Vahabzadeh, S. Hama, G. Hough, N. Kamranpour, et al. Thematic review series: The Pathogenesis of Atherosclerosis The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL J. Lipid Res., June 1, 2004; 45(6): 993 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Rader High-Density Lipoproteins as an Emerging Therapeutic Target for Atherosclerosis JAMA, November 5, 2003; 290(17): 2322 - 2324. [Full Text] [PDF]
|
|